JP2023536633A5 - - Google Patents

Info

Publication number
JP2023536633A5
JP2023536633A5 JP2023507667A JP2023507667A JP2023536633A5 JP 2023536633 A5 JP2023536633 A5 JP 2023536633A5 JP 2023507667 A JP2023507667 A JP 2023507667A JP 2023507667 A JP2023507667 A JP 2023507667A JP 2023536633 A5 JP2023536633 A5 JP 2023536633A5
Authority
JP
Japan
Prior art keywords
heteroalkyl
alkyl
compound
halogen
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536633A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044564 external-priority patent/WO2022031862A2/en
Publication of JP2023536633A publication Critical patent/JP2023536633A/ja
Publication of JP2023536633A5 publication Critical patent/JP2023536633A5/ja
Pending legal-status Critical Current

Links

JP2023507667A 2020-08-04 2021-08-04 ヘテロアリール及びヘテロシクリル化合物 Pending JP2023536633A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063060968P 2020-08-04 2020-08-04
US63/060,968 2020-08-04
PCT/US2021/044564 WO2022031862A2 (en) 2020-08-04 2021-08-04 Heteroaryl and heterocyclyl compounds

Publications (2)

Publication Number Publication Date
JP2023536633A JP2023536633A (ja) 2023-08-28
JP2023536633A5 true JP2023536633A5 (cg-RX-API-DMAC10.html) 2024-08-14

Family

ID=80120142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507667A Pending JP2023536633A (ja) 2020-08-04 2021-08-04 ヘテロアリール及びヘテロシクリル化合物

Country Status (9)

Country Link
US (1) US20230303502A1 (cg-RX-API-DMAC10.html)
EP (1) EP4192468A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023536633A (cg-RX-API-DMAC10.html)
KR (1) KR20230048523A (cg-RX-API-DMAC10.html)
CN (1) CN116322777A (cg-RX-API-DMAC10.html)
AU (1) AU2021321433A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023002132A2 (cg-RX-API-DMAC10.html)
CA (1) CA3190778A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022031862A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4531879A1 (en) 2022-05-25 2025-04-09 Flagship Pioneering Innovations VI, LLC Compositions of secretory and/or catalytic cells and methods using the same
JP2025520113A (ja) 2022-06-03 2025-07-01 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 組成物及び方法
IL328729A (en) 2023-12-01 2026-07-01 Sigilon Therapeutics Inc Methods for producing stem cell-derived islet-like cells, as well as populations and compositions comprising them

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2411197A (en) * 1996-04-30 1997-11-19 Affymax Technologies N.V. Methods for the synthesis of fmoc protected amines
CN103819403B (zh) * 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
ES3036749T3 (en) * 2014-08-01 2025-09-23 Massachusetts Inst Technology Modified alginates for anti-fibrotic materials and applications
EP3215519A1 (en) * 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
US20180185368A1 (en) * 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
CR20180229A (es) * 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
KR20230156818A (ko) * 2016-10-03 2023-11-14 시질론 테라퓨틱스, 인크. 화합물, 장치, 및 이의 용도
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN112203646A (zh) * 2018-04-04 2021-01-08 西吉隆医疗股份有限公司 可植入颗粒和相关方法

Similar Documents

Publication Publication Date Title
US9994567B2 (en) Synthesis of heterocyclic compounds
RU2347778C2 (ru) Новые антагонисты р2х7 рецепторов, способ их получения, фармацевтическая композиция, способ лечения и применение на их основе
JP2024522174A5 (cg-RX-API-DMAC10.html)
JP2021530442A5 (cg-RX-API-DMAC10.html)
JP2020512272A5 (cg-RX-API-DMAC10.html)
CA2632194A1 (en) N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
JP2011527686A5 (cg-RX-API-DMAC10.html)
JP2007511527A5 (cg-RX-API-DMAC10.html)
JP2011219498A5 (cg-RX-API-DMAC10.html)
JP2009542716A5 (cg-RX-API-DMAC10.html)
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
JP2022525069A5 (cg-RX-API-DMAC10.html)
CA2011346A1 (en) 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same
RU2006102127A (ru) Производные хинолина и их применение в терапии
RU2007136535A (ru) Пептидомиметические соединения и получение биологически активных производных
JP2024520832A5 (cg-RX-API-DMAC10.html)
JP2024009799A5 (cg-RX-API-DMAC10.html)
JP2023538524A5 (cg-RX-API-DMAC10.html)
JP2017519796A5 (cg-RX-API-DMAC10.html)
JP2024545787A5 (cg-RX-API-DMAC10.html)
AU2014351354B2 (en) Improved process for the preparation of pomalidomide and its purification
JP2019527724A5 (cg-RX-API-DMAC10.html)
JP2020514299A5 (cg-RX-API-DMAC10.html)
ES2870476T3 (es) Un proceso mejorado para la preparación de diclorhidrato de trientina
RU2007148224A (ru) Производные пиперидин-4-иламида и их применение в качестве антагонистов рецептора sst подтипа 5